NPI: 1326149766 · ABERDEEN, MD 21001 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 09/26/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 09/26/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,584 | $4K |
| 2021 | 2,342 | $28K |
| 2022 | 3,799 | $84K |
| 2023 | 762 | $26K |
| 2024 | 101 | $7K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 2,706 | 320 | $135K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 3,972 | 220 | $11K |
| 83970 | 111 | 106 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | 222 | 61 | $747.89 |
| J1270 | Injection, doxercalciferol, 1 mcg | 528 | 50 | $633.60 |
| A4657 | Syringe, with or without needle, each | 376 | 315 | $88.74 |
| 85048 | 208 | 194 | $0.00 | |
| 85041 | 208 | 194 | $0.00 | |
| 83540 | 77 | 67 | $0.00 | |
| 82108 | 12 | 12 | $0.00 | |
| 83550 | 77 | 67 | $0.00 | |
| 82728 | 72 | 67 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 19 | 12 | $0.00 |